Core Viewpoint - The medical innovation sector is experiencing a structural recovery, with significant inflows into the Medical Innovation ETF and positive performance from key companies in the sector [1][2]. Group 1: Market Performance - On October 29, the Medical Innovation ETF (516820.SH) fell by 1.28%, with component stocks showing mixed results; Chuaning Biological (301301) led gains at 5.12%, while Ailis (688578) saw the largest decline at 5.13% [1]. - The Medical Innovation ETF has seen continuous net inflows over the past five days, with a peak single-day net inflow of 38.68 million yuan, totaling 66.42 million yuan and an average daily net inflow of 13.28 million yuan [1]. Group 2: Industry Trends - The pharmaceutical sector has undergone a prolonged valuation adjustment, but a significant structural recovery trend has emerged recently, supported by policies promoting commercial insurance development [1]. - The investment and financing landscape in the pharmaceutical sector is expected to recover, driven by a rebound in the secondary market, with continued positive sentiment in the CXO and upstream segments [1]. - Recent quarterly reports from several CXO companies, including WuXi AppTec, Tigermed, and others, indicate a positive outlook for the industry [1]. Group 3: Future Outlook - The CXO sector continues to show strong performance, with companies like WuXi AppTec and Boteng surpassing expectations in their quarterly results [2]. - The innovative drug sector is on a long-term upward trend, with opportunities arising from both domestic revenue growth and international expansion [2]. - The expectation of interest rate cuts in the U.S. is likely to enhance global liquidity and support the trend in technology stocks, providing an opportunity for investors to capitalize on the rebound in core pharmaceutical assets through the Medical Innovation ETF [2].

Group 1 - Kanglong Chemical (300759.SZ) reported its Q3 2025 results, with 93 institutional investors holding a total of 748 million shares, representing 42.06% of the total share capital [1] - The top ten institutional investors collectively hold 38.17% of the shares, with a decrease of 0.58 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, 22 funds increased their holdings, accounting for 1.13% of the total, while 27 funds decreased their holdings, representing a reduction of 0.87% [2] - A total of 36 new public funds were disclosed this period, while 489 funds were not disclosed compared to the previous quarter [2] - Foreign investment sentiment showed an increase in holdings from one foreign fund, Hong Kong Central Clearing Limited, with an increase of 0.58% [2]

智通财经APP讯，康龙化成(300759.SZ)发布2025年三季度报告，该公司前三季度营业收入为100.86亿 元，同比增长14.38%。归属于上市公司股东的净利润为11.41亿元，同比减少19.76%。归属于上市公司 股东的扣除非经常性损益的净利润为10.34亿元，同比增长32.04%。基本每股收益为0.6477元。 ...

Core Viewpoint - 康龙化成 (300759.SZ) reported a mixed financial performance for the first three quarters of 2025, with revenue growth but a decline in net profit attributable to shareholders [1] Financial Performance Summary - For the first three quarters of 2025, the company achieved operating revenue of 10.086 billion yuan, an increase of 14.38% year-on-year [1] - The net profit attributable to shareholders was 1.141 billion yuan, a decrease of 19.76% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 1.034 billion yuan, an increase of 32.04% year-on-year [1] - Basic earnings per share were 0.6477 yuan [1] Quarterly Performance Summary - In the third quarter of 2025, the company achieved operating revenue of 3.645 billion yuan, an increase of 13.44% year-on-year [1] - The net profit attributable to shareholders for the third quarter was 440 million yuan, an increase of 42.52% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 397 million yuan, an increase of 25.25% year-on-year [1] - Basic earnings per share for the third quarter were 0.2493 yuan [1]

Group 1: Company Performance - Kanglong Chemical reported Q3 performance with revenue of approximately 10.086 billion yuan, an increase of 14.38% year-on-year [1] - The net profit attributable to shareholders was approximately 1.141 billion yuan, a decrease of 19.76% year-on-year [1] - Basic earnings per share were 0.6477 yuan, down 19.32% year-on-year [1] Group 2: Market Context - As of the report, Kanglong Chemical's market capitalization was 56.8 billion yuan [2] - The A-share market has surpassed 4000 points, indicating a significant market resurgence after a decade of stagnation, with a new "slow bull" market pattern emerging [2]

康龙化成（300759）(03759)发布公告，曾坤鸿先生已自愿辞去其担任的第三届董事会独立非执行董事 职务，以及董事会审计委员会、薪酬与考核委员会及提名委员会委员职务。2025年10月28日，董事会审 议并通过一项决议，提名曾劲峰教授为第三届董事会独立非执行董事的补选候选人。在曾教授于临时股 东大会获委任的前提下，董事会已批准选举曾教授担任董事会审计委员会、薪酬与考核委员会及提名委 员会委员。 ...

证券日报网讯10月28日晚间，康龙化成（300759）发布公告称，董事会同意提名曾劲峰教授为公司第三 届董事会独立非执行董事候选人。 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年10月28日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-055 康龙化成（北京）新药技术股份有限公司 ...

Core Viewpoint - Kanglong Chemical plans to invest 1.346 billion yuan to acquire 82.54% of Wuxi Bai'ao Bio-Science Co., Ltd, enhancing its capabilities in drug discovery services [1] Group 1: Acquisition Details - The acquisition amount is 1.346 billion yuan [1] - Kanglong Chemical aims to strengthen its biological science service capabilities through this acquisition [1] Group 2: Company Profile of Bai'ao Bio - Bai'ao Bio focuses on innovative drug research and development, particularly in the drug discovery phase [1] - The company provides scientific research services based on complex drug target protein preparation, with a core emphasis on structural biology and advantages in cryo-electron microscopy [1] Group 3: Strategic Rationale - The structural analysis biology business of Bai'ao Bio is naturally synergistic with Kanglong Chemical's biological science service business [1] - The acquisition is expected to enhance the service capabilities of Kanglong Chemical's biological science business segment, which has seen rapid and steady revenue growth in recent years [1]

Core Insights - The company reported a revenue of 10.086 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 14.38% [1] - The net profit attributable to shareholders for the same period was 1.141 billion yuan, showing a decline of 19.76% year-on-year [1] - In the third quarter, the company achieved a revenue of 3.645 billion yuan, which is a year-on-year increase of 13.44% [1] - The net profit attributable to shareholders in the third quarter was 440 million yuan, reflecting a significant year-on-year growth of 42.52% [1]